{"id":949,"date":"2023-11-29T14:04:24","date_gmt":"2023-11-29T06:04:24","guid":{"rendered":"https:\/\/cloone.my\/demo\/ijn\/?page_id=949"},"modified":"2023-11-29T20:36:29","modified_gmt":"2023-11-29T12:36:29","slug":"industry-sponsored-research","status":"publish","type":"page","link":"https:\/\/cloone.my\/demo\/ijn\/industry-sponsored-research\/","title":{"rendered":"Industry Sponsored Research"},"content":{"rendered":"

[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”grid” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern” css=”.vc_custom_1701070189557{padding-top: 50px !important;}” z_index=””][vc_column][vc_column_text]<\/p>\n

INDUSTRY SPONSORED RESEARCH<\/span><\/h2>\n

[\/vc_column_text][vc_empty_space height=”20px”][\/vc_column][\/vc_row][vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”grid” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern” css=”.vc_custom_1701237000636{padding-top: 50px !important;padding-bottom: 30px !important;background-color: #ecf5f9 !important;}” z_index=””][vc_column][vc_tabs style=”horizontal”][vc_tab title=”Ongoing” tab_id=”ee6574c9-8bf2-6″][vc_column_text css=”.vc_custom_1701261366099{padding-top: 10px !important;padding-right: 10px !important;padding-bottom: 10px !important;padding-left: 10px !important;background-color: #ffffff !important;}”]<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Ongoing <\/strong>(As at 29 Nov 2022)<\/em><\/span><\/td>\n<\/tr>\n
No.<\/span>
\n<\/strong><\/td>\n		Research Title<\/span>
\n<\/strong><\/td>\n		Investigator<\/span>
\n<\/strong><\/td>\n		Status<\/span>
\n<\/strong><\/td>\n<\/tr>\n
1.<\/td>\nAEGIS II \u2013 A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subject with Acute Coronary Syndrome<\/p>\n

Download<\/a><\/span><\/td>\n

Dato\u2019 Sri Dr. Haji Azhari Rosman<\/td>\nEnrollment<\/td>\n<\/tr>\n
2.<\/td>\nAPPIRED III \u2013 Preventing Oxidative Stress Induced Ischemic Injury and Systemic Inflammation Complications During and After Invasive Cardiac Surgery with Alkaline Phosphatase<\/p>\n

Download<\/a><\/span><\/td>\n

Dr. Pau Kiew Kong<\/td>\nEnrollment<\/td>\n<\/tr>\n
3.<\/td>\nABILITY DIABETES \u2013 Randomized Comparison of Abluminus DES+ Sirolimus-Eluting Stents versus Everolimus-Eluting Stents in Coronary Artery Disease Patients with Diebetes Mellitus Global.<\/p>\n

Download<\/a><\/span><\/td>\n

Dato\u2019 Dr. Amin Ariff Nuruddin<\/td>\nEnrollment<\/td>\n<\/tr>\n
4.<\/td>\nCOMBINE-INTERVENE \u2013 COMBINEd Ischemia and Vulnerable Plaque Percutaneous INTERVENtion to Reduce Cardiovascular Events.<\/p>\n

Download<\/a><\/span><\/td>\n

Dato\u2019 Dr. Amin Ariff Nuruddin<\/td>\nEnrollment<\/td>\n<\/tr>\n
5.<\/td>\nLEADR \u2013 Lead Evaluation for Defibrillation and Reliability<\/p>\n

Download<\/a><\/span><\/td>\n

Dr. Surinder Kaur Khelae<\/td>\nEnrollment<\/td>\n<\/tr>\n
6.<\/td>\nCTO Registry using the HYBRID CTO ALGORITHM at IJN. (Device : Crossboss & Stingray)<\/p>\n

Download<\/a><\/span><\/td>\n

Datuk Dr. Shaiful Azmi Yahaya<\/td>\nEnrollment<\/td>\n<\/tr>\n
7.<\/td>\nFINEARTS \u2013 A multicentre, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure(NYHA II-IV) and EF \u226540%<\/p>\n

Download<\/a><\/span><\/td>\n

Dr. Teoh Chee Kiang<\/td>\nEnrollment<\/td>\n<\/tr>\n
8.<\/td>\nDEDICATE REGISTRY \u2013 A Post Market Registry of Abluminum\u00ae Sirolimus Eluting Coronary Stent System for Percutaneous Intervention in Patients with Diabetic Mellitus<\/p>\n

Download<\/a><\/span><\/td>\n

Dato\u2019 Sri Dr. Haji Azhari Rosman<\/td>\nEnrollment<\/td>\n<\/tr>\n
9.<\/td>\nGSR DEFINE \u2013 Global SYMPLICITY Registry (GSR) Denervation Findings in Real World (DEFINE) is referred to as the GSR DEFINE study<\/p>\n

Download<\/a><\/span><\/td>\n

Dato\u2019 Dr. Amin Ariff Nuruddin<\/td>\nEnrollment<\/td>\n<\/tr>\n
10.<\/td>\nFIM-IBS \u2013 A Prospective, Non-randomized, Open lable, Non-comparative, First-in-Man Study to Evaluate the Feasibility and Safety of Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System<\/p>\n

Download<\/a><\/span><\/td>\n

Datuk Dr. Shaiful Azmi Yahaya<\/td>\nEnrollment<\/td>\n<\/tr>\n
11.<\/td>\nZEUS \u2013 Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation<\/p>\n

Download<\/a><\/span><\/td>\n

Dato\u2019 Sri Dr. Haji Azhari Rosman<\/td>\nEnrollment<\/td>\n<\/tr>\n
12.<\/td>\nMID-Q Response<\/p>\n

Download<\/a><\/span><\/td>\n

Datuk Dr. Azlan Hussin<\/td>\nEnrollment<\/td>\n<\/tr>\n
13.<\/td>\nNEOS-APAC \u2013 Asian Pacific post-market clinical follow-up study in patients with acute or chronic aortic dissection or aortic aneurysm treated with E-vita OPEN NEO<\/p>\n

Download<\/a><\/span><\/td>\n

Mr. Paneer Selvam<\/td>\nEnrollment<\/td>\n<\/tr>\n
14.<\/td>\nRESTORE \u2013 A Prospective, Multicenter, Single-Arm, Open-Label, Phase 4 Study of the Effects of Selexipag on Right Ventricular Remodeling in Pulmonary Arterial Hypertension Assessed by Cardiac Magnetic Resonance Imaging<\/p>\n

Download<\/a><\/span><\/td>\n

Dr. Geetha A\/P Kandavello @ Kandhavel<\/td>\nEnrollment<\/td>\n<\/tr>\n
15.<\/td>\nTOMORROW \u2013 A Multicenter, Open-label, Randomized, Event-driven Study to Assess Efficacy, Safety and Pharmacokinetics of Macitentan Versus Standard of Care in Children with Pulmonary Arterial Hypertension<\/p>\n

Download<\/a><\/span><\/td>\n

Dr. Geetha A\/P Kandavello @ Kandhavel<\/td>\nEnrollment<\/td>\n<\/tr>\n
16.<\/td>\nVFAHF STUDY \u2013 Ventricle from Atrium Heart Failure Clinical Study (VFAHF)<\/p>\n

Download<\/a><\/span><\/td>\n

Datuk Dr. Azlan Hussin<\/td>\nEnrollment<\/td>\n<\/tr>\n
17.<\/td>\nSALTO \u2013 A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Event-Driven, Group-Sequential Study with Open-Label Extension Period to Assess the Efficacy and Safety of Selexipag as Add-On Treatment to Standard of Care in Children Aged \u22652 to <18 years with Pulmonary Arterial Hypertension<\/p>\n

Download<\/a><\/span><\/td>\n

Dr. Geetha A\/P Kandavello @ Kandhavel<\/td>\nEnrollment<\/td>\n<\/tr>\n
18.<\/td>\nSCORE REGISTRY \u2013 Sequent\u00ae SCB \u2018\u2019All Comers\u2019\u2019 Post Market Clinical Follow up (PMCF)<\/p>\n

Download<\/a><\/span><\/td>\n

Dato\u2019 Dr. Amin Ariff Nuruddin<\/td>\nEnrollment<\/td>\n<\/tr>\n
19.<\/td>\nSTRIDE \u2013 Effects of semaglutide on functional capacity in patients withtype 2 diabetes and peripheral arterial disease<\/p>\n

Download<\/a><\/span><\/td>\n

Datuk Dr. Shaiful Azmi Yahaya<\/td>\nEnrollment<\/td>\n<\/tr>\n
20.<\/td>\nPRIME-FFR \u2013 Prognostic impact of lesion-specific hemodynamic index and disease characteristics in patients with coronary artery disease assessed by fractional flow reserve<\/p>\n

Download<\/a><\/span><\/td>\n

Datuk Dr. Azlan Hussin<\/td>\nEnrollment<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

[\/vc_column_text][vc_column_text css=”.vc_custom_1701261377692{padding-top: 10px !important;padding-right: 10px !important;padding-bottom: 10px !important;padding-left: 10px !important;background-color: #ffffff !important;}”]<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Ongoing <\/strong>(As at 29 Nov 2022)<\/em><\/span><\/td>\n<\/tr>\n
No.<\/span>
\n<\/strong><\/td>\n		Research Title<\/span><\/strong><\/td>\nInvestigator<\/span>
\n<\/strong><\/td>\n		Status<\/span>
\n<\/strong><\/td>\n<\/tr>\n
1.<\/td>\nBIOLUX P-III REGISTRY \u2013 BIOTRONIK-A Prospective, International, Multi-Centre, Post-Market All-Comers Registry To Assess The Clinical Performance Of The Passeo-18 Lux Paclitaxel Releasing Balloon Catheter In Infraguinal Arteries -III<\/p>\n

Download<\/a><\/span><\/td>\n

Datuk Dr. Shaiful Azmi Yahaya<\/td>\nFollow Up<\/td>\n<\/tr>\n
2.<\/td>\nMeres-1 Extend \u2013 A Prospective, Multinational, Multicenter, Single Arm, Open Label, Pilot Clinical Study Of Meres100 Sirolimus Eluting Bioresorbable Vascular Scaffold System In The Treatment Of De-Novo Native Coronary Artery Lesions<\/p>\n

Download<\/a><\/span><\/td>\n

Dato\u2019 Dr. Amin Ariff Nuruddin<\/td>\nFollow Up<\/td>\n<\/tr>\n
3.<\/td>\nABSORB BVS \u2013 Comparative Study In Real World Use Of The ABSORB Bioresorbable Vascular Scaffold In De Novo Coronary Artery Disease Among Diabetes And Non-Diabetes Patient In Institut Jantung Negara, Malaysia: A Prospective Post-Marketing Single-Center Registry<\/p>\n

Download<\/a><\/span><\/td>\n

Datuk Dr. Shaiful Azmi Yahaya<\/td>\nFollow Up<\/td>\n<\/tr>\n
4.<\/td>\nCONSEQUENT ALL COMERS \u2013 Clinical PMCF on Peripheral Arteries treated with SeQuent\u00ae Please OTW Paclitaxel Coated Balloon Catheter in an All Comer Patient Population<\/p>\n

Download<\/a><\/span><\/td>\n

Datuk Dr. Shaiful Azmi Yahaya<\/td>\nFollow Up<\/td>\n<\/tr>\n
5.<\/td>\nISCHEMIA \u2013 International Study of Comparative Health Effectiveness With Medical and Invasive Approaches<\/p>\n

Download<\/a><\/span><\/td>\n

Datuk Dr. Ahmad Khairuddin Mohamed Yusof<\/td>\nFollow Up<\/td>\n<\/tr>\n
6.<\/td>\nThe EASTBOURNE Registry \u2013 The All-comers Sirolimus-coated balloon European registry<\/p>\n

Download<\/a><\/span><\/td>\n

Dato\u2019 Dr. Amin Ariff Nuruddin<\/td>\nFollow Up<\/td>\n<\/tr>\n
7.<\/td>\nSCB DE-NOVO STUDY \u2013 Treatment of coronary de-novo stenosis by a sirolimus coated balloon or a paclitaxel coated balloon catheter<\/p>\n

Download<\/a><\/span><\/td>\n

Dato\u2019 Dr. Amin Ariff Nuruddin<\/td>\nFollow Up<\/td>\n<\/tr>\n
8.<\/td>\nBIOSOLVE-IV REGISTRY \u2013 Safety And Performance In De Novo Lesion Of Native Coronary Arteries With Magmaris \u2013 Registry Data<\/p>\n

Download<\/a><\/span><\/td>\n

Dato\u2019 Dr. Amin Ariff Nuruddin<\/td>\nFollow Up<\/td>\n<\/tr>\n
9.<\/td>\nMYHF \u2013 Malaysian National Heart Failure Registry<\/p>\n

Download<\/a><\/span><\/td>\n

Dato\u2019 Dr. Azmee Bin Mohd Ghazi<\/td>\nFollow Up<\/td>\n<\/tr>\n
10.<\/td>\nSELECT STUDY \u2013 Semaglutide effects on cardiovascular outcomes in people with overweight or obesity<\/p>\n

Download<\/a><\/span><\/td>\n

Dato\u2019 Sri Dr. Haji Azhari Rosman<\/td>\nFollow Up<\/td>\n<\/tr>\n
11.<\/td>\nBGSAMIRP \u2013 Blood-based Genomic Signatures in Acute Myocardial Infarction Risk Prediction<\/p>\n

Download<\/a><\/span><\/td>\n

Dato\u2019 Dr. Amin Ariff Nuruddin<\/td>\nFollow Up<\/td>\n<\/tr>\n
12.<\/td>\nCAAN-AF \u2013 Cardiac Resynchronization therapy (CRT) And AV Node ablation in Atrial Fibrillation<\/p>\n

Download<\/a><\/span><\/td>\n

Datuk Dr. Azlan Hussin<\/td>\nFollow Up<\/td>\n<\/tr>\n
13.<\/td>\nPROTECT-ICD Trial \u2013 Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction<\/p>\n

Download<\/a><\/span><\/td>\n

Dr. Geetha A\/P Kandavello @ Kandhavel<\/td>\nFollow Up<\/td>\n<\/tr>\n
14.<\/td>\nCRYO AF GLOBAL REGISTRY<\/p>\n

Download<\/a><\/span><\/td>\n

Dr. Surinder Kaur Khelae<\/td>\nFollow Up<\/td>\n<\/tr>\n
15.<\/td>\nA DUE \u2013 Prospective, multi-center, double-blind, randomized, active-controlled, triple-dummy, parallel-group, group-sequential, adaptive Phase 3 clinical study to compare the efficacy and safety of macitentan and tadalafil monotherapies with the corresponding fixed dose combination in subjects with pulmonary arterial hypertension (PAH), followed by an open-label treatment period with macitentan and tadalafil fixed dose combination therapy<\/p>\n

Download<\/a><\/span><\/td>\n

Dr. Geetha A\/P Kandavello @ Kandhavel<\/td>\nFollow Up<\/td>\n<\/tr>\n
16.<\/td>\nBIOFLOW-DAPT \u2013 BIOTRONIK \u2013 A Prospective, Randomized, Multi-center Study to Assess the SaFety of the Orsiro Mission Stent compared to the ResoLute Onyx Stent in Subjects at High Risk for Bleeding in combination With 1-month Dual Antiplatelet Therapy (DAPT)<\/p>\n

Download<\/a><\/span><\/td>\n

Datuk Dr. Shaiful Azmi Yahaya<\/td>\nFollow Up<\/td>\n<\/tr>\n
17.<\/td>\nMICRA AV \u2013 Product Surveillance Registry (PSR)<\/p>\n

Download<\/a><\/span><\/td>\n

Datuk Dr. Azlan Hussin<\/td>\nFollow Up<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

[\/vc_column_text][\/vc_tab][vc_tab title=”Completed” tab_id=”940aaf0f-3f65-0″][vc_column_text css=”.vc_custom_1701261387846{padding-top: 10px !important;padding-right: 10px !important;padding-bottom: 10px !important;padding-left: 10px !important;background-color: #ffffff !important;}”]<\/p>\n\n\n\n\n\n\n
Completed <\/strong>(As at 29 Nov 2022)<\/em><\/span><\/td>\n<\/tr>\n
No.<\/span>
\n<\/strong><\/td>\n		Research Title<\/span><\/strong><\/td>\nInvestigator<\/span>
\n<\/strong><\/td>\n		Status<\/span>
\n<\/strong><\/td>\n<\/tr>\n
–<\/td>\nResearch are in progress..<\/em><\/span><\/td>\n–<\/td>\n–<\/td>\n<\/tr>\n
–<\/td>\nResearch are in progress..<\/em><\/span><\/td>\n–<\/td>\n–<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

[\/vc_column_text][\/vc_tab][\/vc_tabs][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”grid” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern” css=”.vc_custom_1701070189557{padding-top: 50px !important;}” z_index=””][vc_column][vc_column_text] INDUSTRY SPONSORED RESEARCH [\/vc_column_text][vc_empty_space height=”20px”][\/vc_column][\/vc_row][vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”grid” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern” css=”.vc_custom_1701237000636{padding-top: 50px !important;padding-bottom: 30px !important;background-color: #ecf5f9 !important;}” z_index=””][vc_column][vc_tabs style=”horizontal”][vc_tab title=”Ongoing” tab_id=”ee6574c9-8bf2-6″][vc_column_text css=”.vc_custom_1701261366099{padding-top: 10px !important;padding-right: 10px !important;padding-bottom: 10px !important;padding-left: 10px !important;background-color: #ffffff…<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"full_width.php","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-949","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/cloone.my\/demo\/ijn\/wp-json\/wp\/v2\/pages\/949","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cloone.my\/demo\/ijn\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cloone.my\/demo\/ijn\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/cloone.my\/demo\/ijn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cloone.my\/demo\/ijn\/wp-json\/wp\/v2\/comments?post=949"}],"version-history":[{"count":16,"href":"https:\/\/cloone.my\/demo\/ijn\/wp-json\/wp\/v2\/pages\/949\/revisions"}],"predecessor-version":[{"id":969,"href":"https:\/\/cloone.my\/demo\/ijn\/wp-json\/wp\/v2\/pages\/949\/revisions\/969"}],"wp:attachment":[{"href":"https:\/\/cloone.my\/demo\/ijn\/wp-json\/wp\/v2\/media?parent=949"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}